. Author manuscript; available in PMC: 2014 Feb 1.

Published in final edited form as: Cancer Chemother Pharmacol. 2012 Oct 30;71(2):331–344. doi: 10.1007/s00280-012-2010-z

Table 1 (b).

Concentrations and AUCs of kb-NB165-09 in plasma and tissues after administration of 25 mg/kg kb-NB165-09 iv to C.B-17 SCID female mice bearing PANC-1 xenografts

Time (Min)	Plasma (nmol/mL)	Tumor (nmol/g)	Liver (nmol/g)	Kidney (nmol/g)
5	61.9±9.4	6.46±2.39	42.6±6.4	94.8±1.3
10	24.8±4.2	6.52±1.31	25.7±3.6	56.4±8.0
15	21.9±1.8	8.01±1.72	22.6±3.6	30.5±1.5
30	8.94±2.45	7.00±2.28	11.3±0.8	22.4±6.1
60	0.54±0.14	2.61±0.54	2.77±0.14	5.03±0.15
120	0.21±0.12	1.45±0.04	0.20	ND
240	ND	0.64±0.02	ND	ND
AUC_0→∞ (nmol·min/mL) or (nmol·min/g)	782	604	854	1724